{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:41:04Z","timestamp":1773294064780,"version":"3.50.1"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40272-022-00517-y","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T04:02:30Z","timestamp":1656907350000},"page":"465-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacotherapy of Disruptive Behaviors in Children with Intellectual Disabilities"],"prefix":"10.1007","volume":"24","author":[{"given":"Gabrielle E.","family":"Hodgins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Winsor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarrett","family":"Barnhill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"issue":"5","key":"517_CR1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/cch.12873","volume":"47","author":"D Reddihough","year":"2021","unstructured":"Reddihough D, Leonard H, Jacoby P, et al. Comorbidities and quality of life in children with intellectual disability. Child Care Health Dev. 2021;47(5):654\u201366. https:\/\/doi.org\/10.1111\/cch.12873.","journal-title":"Child Care Health Dev"},{"issue":"6","key":"517_CR2","first-page":"657","volume":"41","author":"MF Hayden","year":"1996","unstructured":"Hayden MF, Goldman J. Families of adults with mental retardation: stress levels and need for services. Soc Work. 1996;41(6):657\u201367.","journal-title":"Soc Work"},{"issue":"4","key":"517_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10803-005-5030-2","volume":"35","author":"GH Murphy","year":"2005","unstructured":"Murphy GH, Beadle-Brown J, Wing L, et al. Chronicity of challenging behaviours in people with severe intellectual disabilities and\/or autism: a total population sample. J Autism Dev Disord. 2005;35(4):405\u201318. https:\/\/doi.org\/10.1007\/s10803-005-5030-2.","journal-title":"J Autism Dev Disord"},{"key":"517_CR4","unstructured":"Deb S, Bethea T, Havercamp SM, et al. Disruptive, impulse control and conduct disorders. In: Fletcher RJ, National Association of the Dually Diagnosed, American Psychiatric Association, et al. DM-ID 2: diagnostic manual - intellectual disability; a textbook of diagnosis of mental disorders in persons with intellectual disability. 2nd ed. Kingston, NY, NADD Press; 2016."},{"key":"517_CR5","doi-asserted-by":"publisher","unstructured":"Pessoa L. The emotional brain. In: Conn. Conn\u2019s translational neuroscience. Amsterdam, Elsevier; 2017: p. 635\u201356. https:\/\/doi.org\/10.1016\/B978-0-12-802381-5.00046-4.","DOI":"10.1016\/B978-0-12-802381-5.00046-4"},{"key":"517_CR6","unstructured":"Gardner W, Griffiths D. Treatment of aggression and related disruptive behavior Disorders in persons with developmental disorders. In: Matson JL, Laud RB, Matson ML, et al. Behavior modification for persons with developmental disabilities: treatments and support. 1st ed. Kingston, NY, NADD Press; 2004."},{"key":"517_CR7","unstructured":"Sturmey P, Bernstein H. Functional analysis of maladaptive behavior. In: Matson JL, Laud RB, Matson ML, et al. Behavior modification for persons with developmental disabilities: treatments and support. 1st ed. Kingston, NY, NADD Press; 2004."},{"key":"517_CR8","unstructured":"Lester B, Marsit C, Bromer C. Behavioral epigenetics and the developmental origins of child mental health disorders. In: Brandt K, Perry BD, Seligman S, et al. Infant and early childhood mental health: core concepts and clinical practice. 1st ed. Washington, DC, American Psychiatric Publishing, a Division of American Psychiatric Association; 2014."},{"key":"517_CR9","unstructured":"Fries A, Pollak S. Emotion processing and the developing brain. In: Coch, Dawson, and Fischer. Human behavior, learning, and the developing brain. New York, NY, Guilford Press; 2007; p. 329\u201361."},{"issue":"3","key":"517_CR10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.chc.2007.02.002","volume":"16","author":"M Schaer","year":"2007","unstructured":"Schaer M, Eliez S. From genes to brain: understanding brain development in neurogenetic disorders using neuroimaging techniques. Child Adolesc Psychiatr Clin N Am. 2007;16(3):557\u201379. https:\/\/doi.org\/10.1016\/j.chc.2007.02.002.","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"1","key":"517_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2788.2005.00656.x","volume":"49","author":"A Dosen","year":"2005","unstructured":"Dosen A. Applying the developmental perspective in the psychiatric assessment and diagnosis of persons with intellectual disability: part I\u2014assessment. J Intellect Disabil Res. 2005;49(1):1\u20138. https:\/\/doi.org\/10.1111\/j.1365-2788.2005.00656.x.","journal-title":"J Intellect Disabil Res"},{"key":"517_CR12","unstructured":"Kagan J, Snidman N. Temperament and biology. In: Coch, Dawson, and Fischer. Human behavior, learning, and the developing brain. New York, NY, Guilford Press; 2007; p. 219\u201346."},{"key":"517_CR13","unstructured":"Siegel DJ. The developing mind: how relationships and the brain interact to shape who we are. 2nd ed. New York, NY, Guilford Press; 2012."},{"issue":"5","key":"517_CR14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1469-7610.2011.02478.x","volume":"53","author":"AM Addington","year":"2012","unstructured":"Addington AM, Rapoport JL. Annual research review: impact of advances in genetics in understanding developmental psychopathology: impact of advances in genetics. J Child Psychol Psychiatry. 2012;53(5):510\u20138. https:\/\/doi.org\/10.1111\/j.1469-7610.2011.02478.x.","journal-title":"J Child Psychol Psychiatry"},{"issue":"3","key":"517_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.chc.2009.03.001","volume":"18","author":"DS Schechter","year":"2009","unstructured":"Schechter DS, Willheim E. Disturbances of attachment and parental psychopathology in early childhood. Child Adolesc Psychiatr Clin N Am. 2009;18(3):665\u201386. https:\/\/doi.org\/10.1016\/j.chc.2009.03.001.","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"2","key":"517_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ridd.2010.12.018","volume":"32","author":"PK Maulik","year":"2011","unstructured":"Maulik PK, Mascarenhas MN, Mathers CD, et al. Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil. 2011;32(2):419\u201336. https:\/\/doi.org\/10.1016\/j.ridd.2010.12.018.","journal-title":"Res Dev Disabil"},{"key":"517_CR17","unstructured":"Tass\u00e9 MJ, Bertelli M, Simon E, et al. Intellectual disability (intellectual developmental disorder). In: Fletcher RJ, National Association of the Dually Diagnosed, American Psychiatric Association, et al. DM-ID 2: diagnostic manual\u2014intellectual disability\u202f; a textbook of diagnosis of mental disorders in persons with intellectual disability. 2nd ed. Kingston, NY, NADD Press; 2016: p. 75\u201391."},{"key":"517_CR18","unstructured":"Boat TF, Wu JT. Clinical characteristics of intellectual disabilities. National Academies Press (US); 2015. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK332877\/. Accessed 29 Oct 2021."},{"key":"517_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2020.103718","volume":"104","author":"G Balboni","year":"2020","unstructured":"Balboni G, Rebecchini G, Elisei S, et al. Factors affecting the relationship between adaptive behavior and challenging behaviors in individuals with intellectual disability and co-occurring disorders. Res Dev Disabil. 2020;104: 103718. https:\/\/doi.org\/10.1016\/j.ridd.2020.103718.","journal-title":"Res Dev Disabil"},{"key":"517_CR20","doi-asserted-by":"publisher","unstructured":"Barnhill J. Introduction to mental health and behavior. In: Rubin IL, Merrick J, Greydanus DE, et al. Health care for people with intellectual and developmental disabilities across the lifespan. Switzerland, Springer International Publishing; 2016: p. 1481\u20137. https:\/\/doi.org\/10.1007\/978-3-319-18096-0_119.","DOI":"10.1007\/978-3-319-18096-0_119"},{"key":"517_CR21","unstructured":"Emerson E. Challenging behaviour: analysis and intervention in people with intellectual disabilities. Cambridge, UK, Cambridge University Press; 2001. https:\/\/eprints.lancs.ac.uk\/id\/eprint\/13523\/. Accessed 28 Oct 2021."},{"issue":"1","key":"517_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1098-2779(2000)6:1<1::AID-MRDD1>3.0.CO;2-J","volume":"6","author":"JJ Volpe","year":"2000","unstructured":"Volpe JJ. Overview: normal and abnormal human brain development. Ment Retard Dev Disabil Res Rev. 2000;6(1):1\u20135. https:\/\/doi.org\/10.1002\/(SICI)1098-2779(2000)6:1%3c1::AID-MRDD1%3e3.0.CO;2-J.","journal-title":"Ment Retard Dev Disabil Res Rev"},{"issue":"1","key":"517_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/(SICI)1098-2779(2000)6:1<41::AID-MRDD6>3.0.CO;2-V","volume":"6","author":"SL Pomeroy","year":"2000","unstructured":"Pomeroy SL, Kim JYH. Biology and pathobiology of neuronal development. Ment Retard Dev Disabil Res Rev. 2000;6(1):41\u20136. https:\/\/doi.org\/10.1002\/(SICI)1098-2779(2000)6:1%3c41::AID-MRDD6%3e3.0.CO;2-V.","journal-title":"Ment Retard Dev Disabil Res Rev"},{"issue":"2","key":"517_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/pch\/17.2.84","volume":"17","author":"S Ageranioti-B\u00e9langer","year":"2012","unstructured":"Ageranioti-B\u00e9langer S, Brunet S, D\u2019Anjou G, et al. Behaviour disorders in children with an intellectual disability. Paediatr Child Health. 2012;17(2):84\u20138. https:\/\/doi.org\/10.1093\/pch\/17.2.84.","journal-title":"Paediatr Child Health"},{"issue":"3","key":"517_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1176\/appi.focus.10.3.300","volume":"10","author":"J Barnhill","year":"2012","unstructured":"Barnhill J, McNelis D. Overview of intellectual\/developmental disabilities. Focus. 2012;10(3):300\u20137. https:\/\/doi.org\/10.1176\/appi.focus.10.3.300.","journal-title":"Focus"},{"issue":"11","key":"517_CR26","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1176\/appi.ajp.2021.21090944","volume":"178","author":"DG Gee","year":"2021","unstructured":"Gee DG. Early adversity and development: parsing heterogeneity and identifying pathways of risk and resilience. Am J Psychiatry. 2021;178(11):998\u20131013. https:\/\/doi.org\/10.1176\/appi.ajp.2021.21090944.","journal-title":"Am J Psychiatry"},{"issue":"11","key":"517_CR27","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/archpsyc.59.11.996","volume":"59","author":"M Rutter","year":"2002","unstructured":"Rutter M. The interplay of nature, nurture, and developmental influences: the challenge ahead for mental health. Arch Gen Psychiatry. 2002;59(11):996. https:\/\/doi.org\/10.1001\/archpsyc.59.11.996.","journal-title":"Arch Gen Psychiatry"},{"key":"517_CR28","unstructured":"Matson JL, Laud RB, Matson ML, et al. Behavior modification for persons with developmental disabilities: treatments and support. 1st ed. Kingston, NY, NADD Press; 2004."},{"issue":"2","key":"517_CR29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1037\/0012-1649.39.2.222","volume":"39","author":"LM Broidy","year":"2003","unstructured":"Broidy LM, Nagin DS, Tremblay RE, et al. Developmental trajectories of childhood disruptive behaviors and adolescent delinquency: a six-Site, cross-national study. Dev Psychol. 2003;39(2):222\u201345. https:\/\/doi.org\/10.1037\/0012-1649.39.2.222.","journal-title":"Dev Psychol"},{"issue":"4","key":"517_CR30","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10578-012-0349-3","volume":"44","author":"CJ Trentacosta","year":"2013","unstructured":"Trentacosta CJ, Hyde LW, Goodlett BD, et al. Longitudinal prediction of disruptive behavior disorders in adolescent males from multiple risk domains. Child Psychiatry Hum Dev. 2013;44(4):561\u201372. https:\/\/doi.org\/10.1007\/s10578-012-0349-3.","journal-title":"Child Psychiatry Hum Dev"},{"issue":"3","key":"517_CR31","first-page":"85","volume":"6","author":"J Barnhill","year":"2003","unstructured":"Barnhill J. Can the DSM-IV-TR be salvaged for individuals with severe developmental disabilities? Ment Health Asp Dev Disabil. 2003;6(3):85\u201398.","journal-title":"Ment Health Asp Dev Disabil."},{"issue":"9","key":"517_CR32","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1176\/appi.ajp.2018.17121383","volume":"175","author":"A Caspi","year":"2018","unstructured":"Caspi A, Moffitt TE. All for one and one for all: mental disorders in one dimension. Am J Psychiatry. 2018;175(9):831\u201344. https:\/\/doi.org\/10.1176\/appi.ajp.2018.17121383.","journal-title":"Am J Psychiatry"},{"issue":"4 Pt 2","key":"517_CR33","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1017\/S0954579413000722","volume":"25","author":"E Leibenluft","year":"2013","unstructured":"Leibenluft E, Stoddard J. The developmental psychopathology of irritability. Dev Psychopathol. 2013;25(4 Pt 2):1473\u201387. https:\/\/doi.org\/10.1017\/S0954579413000722.","journal-title":"Dev Psychopathol"},{"issue":"6","key":"517_CR34","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1176\/appi.ajp.2016.16070839","volume":"174","author":"MA Brotman","year":"2017","unstructured":"Brotman MA, Kircanski K, Stringaris A, et al. Irritability in youths: a translational model. Am J Psychiatry. 2017;174(6):520\u201332. https:\/\/doi.org\/10.1176\/appi.ajp.2016.16070839.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"517_CR35","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1176\/appi.ajp.2015.15060833","volume":"173","author":"JL Wiggins","year":"2016","unstructured":"Wiggins JL, Brotman MA, Adleman NE, et al. Neural correlates of irritability in disruptive mood dysregulation and bipolar disorders. Am J Psychiatry. 2016;173(7):722\u201330. https:\/\/doi.org\/10.1176\/appi.ajp.2015.15060833.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"517_CR36","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/j.1365-2788.2011.01418.x","volume":"55","author":"JA Tsiouris","year":"2011","unstructured":"Tsiouris JA, Kim SY, Brown WT, et al. Association of aggressive behaviours with psychiatric disorders, age, sex and degree of intellectual disability: a large-scale survey. J Intellect Disabil Res. 2011;55(7):636\u201349. https:\/\/doi.org\/10.1111\/j.1365-2788.2011.01418.x.","journal-title":"J Intellect Disabil Res"},{"issue":"7","key":"517_CR37","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jaac.2013.04.014","volume":"52","author":"K Boylan","year":"2013","unstructured":"Boylan K, Macpherson HA, Fristad MA. Examination of disruptive behavior outcomes and moderation in a randomized psychotherapy trial for mood disorders. J Am Acad Child Adolesc Psychiatry. 2013;52(7):699\u2013708. https:\/\/doi.org\/10.1016\/j.jaac.2013.04.014.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"517_CR38","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1176\/appi.ajp.2017.17010045","volume":"175","author":"LS Wakschlag","year":"2018","unstructured":"Wakschlag LS, Perlman SB, Blair RJ, et al. The neurodevelopmental basis of early childhood disruptive behavior: irritable and callous phenotypes as exemplars. Am J Psychiatry. 2018;175(2):114\u201330. https:\/\/doi.org\/10.1176\/appi.ajp.2017.17010045.","journal-title":"Am J Psychiatry"},{"key":"517_CR39","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association, editor. Diagnostic and statistical manual of mental disorders. Fifth Edition. Washington DC, APA Publishing; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"517_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1352\/1934-9556-56.2.147","volume":"56","author":"N Bouras","year":"2018","unstructured":"Bouras N. Book review: diagnostic manual - intellectual Disability (DM-ID 2): textbook of diagnosis of mental disorders in persons with intellectual disability. Intellect Dev Disabil. 2018;56:147\u201350. https:\/\/doi.org\/10.1352\/1934-9556-56.2.147.","journal-title":"Intellect Dev Disabil"},{"key":"517_CR41","doi-asserted-by":"publisher","unstructured":"Lahey BB, Waldman ID. Personality dispositions and the development of violence and conduct problems. In: Flannery DJ, Vazsonyi AT, Waldman ID, editors. The Cambridge handbook of violent behavior and aggression. Cambridge, UK, Cambridge University Press; 2007: p. 260\u201387. https:\/\/doi.org\/10.1017\/CBO9780511816840.013.","DOI":"10.1017\/CBO9780511816840.013"},{"issue":"8","key":"517_CR42","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1176\/appi.ajp.2019.18101134","volume":"176","author":"L Riglin","year":"2019","unstructured":"Riglin L, Eyre O, Thapar AK, et al. Identifying novel types of irritability using a developmental genetic approach. Am J Psychiatry. 2019;176(8):635\u201342. https:\/\/doi.org\/10.1176\/appi.ajp.2019.18101134.","journal-title":"Am J Psychiatry"},{"key":"517_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.paid.2019.02.031","volume":"144","author":"CM Deveney","year":"2019","unstructured":"Deveney CM, Stoddard J, Evans R, et al. On defining irritability and its relationship to affective traits and social interpretations. Pers Individ Dif. 2019;144:61\u20137. https:\/\/doi.org\/10.1016\/j.paid.2019.02.031.","journal-title":"Pers Individ Dif"},{"issue":"4","key":"517_CR44","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1176\/appi.ajp.2008.07111774","volume":"165","author":"LJ Siever","year":"2008","unstructured":"Siever LJ. Neurobiology of aggression and violence. Am J Psychiatry. 2008;165(4):429\u201342. https:\/\/doi.org\/10.1176\/appi.ajp.2008.07111774.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"517_CR45","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.beth.2019.10.009","volume":"51","author":"TP Beauchaine","year":"2020","unstructured":"Beauchaine TP, Tackett JL. Irritability as a transdiagnostic vulnerability trait: current issues and future directions. Behav Ther. 2020;51(2):350\u201364. https:\/\/doi.org\/10.1016\/j.beth.2019.10.009.","journal-title":"Behav Ther"},{"issue":"Pt 6","key":"517_CR46","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1046\/j.1365-2788.2003.00517.x","volume":"47","author":"K McClintock","year":"2003","unstructured":"McClintock K, Hall S, Oliver C. Risk markers associated with challenging behaviours in people with intellectual disabilities: a meta-analytic study. J Intellect Disabil Res. 2003;47(Pt 6):405\u201316. https:\/\/doi.org\/10.1046\/j.1365-2788.2003.00517.x.","journal-title":"J Intellect Disabil Res"},{"issue":"7","key":"517_CR47","doi-asserted-by":"publisher","first-page":"967","DOI":"10.4088\/JCP.08m04429","volume":"70","author":"RJ Fletcher","year":"2009","unstructured":"Fletcher RJ, Havercamp SM, Ruedrich SL, et al. Clinical usefulness of the diagnostic manual-intellectual disability for mental disorders in persons with intellectual disability: results from a brief field survey. J Clin Psychiatry. 2009;70(7):967\u201374. https:\/\/doi.org\/10.4088\/JCP.08m04429.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"517_CR48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0272-7358(93)90016-F","volume":"13","author":"PJ Frick","year":"1993","unstructured":"Frick PJ, Lahey BB, Loeber R, et al. Oppositional defiant disorder and conduct disorder: a meta-analytic review of factor analyses and cross-validation in a clinic sample. Clin Psychol Rev. 1993;13(4):319\u201340. https:\/\/doi.org\/10.1016\/0272-7358(93)90016-F.","journal-title":"Clin Psychol Rev"},{"issue":"7","key":"517_CR49","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/jcpp.12353","volume":"56","author":"J Silberg","year":"2015","unstructured":"Silberg J, Moore AA, Rutter M. Age of onset and the subclassification of conduct\/dissocial disorder. J Child Psychol Psychiatry. 2015;56(7):826\u201333. https:\/\/doi.org\/10.1111\/jcpp.12353.","journal-title":"J Child Psychol Psychiatry"},{"issue":"1","key":"517_CR50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/0145445507304581","volume":"32","author":"JL Matson","year":"2008","unstructured":"Matson JL, Lovullo SV. A review of behavioral treatments for self-injurious behaviors of persons with autism spectrum disorders. Behav Modif. 2008;32(1):61\u201376. https:\/\/doi.org\/10.1177\/0145445507304581.","journal-title":"Behav Modif"},{"issue":"1","key":"517_CR51","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jaac.2012.10.001","volume":"52","author":"JS Comer","year":"2013","unstructured":"Comer JS, Chow C, Chan PT, et al. Psychosocial treatment efficacy for disruptive behavior problems in very young children: a meta-analytic examination. J Am Acad Child Adolesc Psychiatry. 2013;52(1):26\u201336. https:\/\/doi.org\/10.1016\/j.jaac.2012.10.001.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"517_CR52","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1176\/appi.ajp.2018.18030355","volume":"176","author":"MK Jha","year":"2019","unstructured":"Jha MK, Minhajuddin A, South C, et al. Irritability and its clinical utility in major depressive disorder: prediction of individual-level acute-phase outcomes using early changes in irritability and depression severity. Am J Psychiatry. 2019;176(5):358\u201366. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18030355.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"517_CR53","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/00004583-200004000-00021","volume":"39","author":"RL Findling","year":"2000","unstructured":"Findling RL, McNamara NK, Branicky LA, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000;39(4):509\u201316. https:\/\/doi.org\/10.1097\/00004583-200004000-00021.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"517_CR54","doi-asserted-by":"publisher","unstructured":"Loy JH, Merry SN, Hetrick SE, et al. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev. 2017;2017(8):CD008559. https:\/\/doi.org\/10.1002\/14651858.CD008559.pub3.","DOI":"10.1002\/14651858.CD008559.pub3"},{"issue":"8","key":"517_CR55","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1176\/appi.ajp.159.8.1337","volume":"159","author":"MG Aman","year":"2002","unstructured":"Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159(8):1337\u201346. https:\/\/doi.org\/10.1176\/appi.ajp.159.8.1337.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"517_CR56","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1097\/00004583-200209000-00002","volume":"41","author":"R Snyder","year":"2002","unstructured":"Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;41(9):1026\u201336. https:\/\/doi.org\/10.1097\/00004583-200209000-00002.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"517_CR57","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1176\/appi.ajp.161.4.677","volume":"161","author":"RL Findling","year":"2004","unstructured":"Findling RL, Aman MG, Eerdekens M, et al. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry. 2004;161(4):677\u201384. https:\/\/doi.org\/10.1176\/appi.ajp.161.4.677.","journal-title":"Am J Psychiatry"},{"key":"517_CR58","doi-asserted-by":"crossref","unstructured":"Aman MG, Gharabawi GM, Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental Retardation and Developmental Disabilities. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. J Clin Psychiatry. 2004;65(9):1197\u2013210.","DOI":"10.4088\/JCP.v65n0907"},{"key":"517_CR59","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ridd.2018.08.017","volume":"83","author":"N Tarrant","year":"2018","unstructured":"Tarrant N, Roy M, Deb S, et al. The effectiveness of methylphenidate in the management of attention deficit hyperactivity disorder (ADHD) in people with intellectual disabilities: a systematic review. Res Dev Disabil. 2018;83:217\u201332. https:\/\/doi.org\/10.1016\/j.ridd.2018.08.017.","journal-title":"Res Dev Disabil"},{"issue":"3","key":"517_CR60","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1207\/s15374424jccp2003_9","volume":"20","author":"SP Hinshaw","year":"1991","unstructured":"Hinshaw SP. Stimulant medication and the treatment of aggression in children with attentional deficits. J Clin Child Psychol. 1991;20(3):301\u201312. https:\/\/doi.org\/10.1207\/s15374424jccp2003_9.","journal-title":"J Clin Child Psychol"},{"issue":"1","key":"517_CR61","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12888-017-1332-0","volume":"17","author":"T Sparding","year":"2017","unstructured":"Sparding T, P\u00e5lsson E, Joas E, et al. Personality traits in bipolar disorder and influence on outcome. BMC Psychiatry. 2017;17(1):159. https:\/\/doi.org\/10.1186\/s12888-017-1332-0.","journal-title":"BMC Psychiatry"},{"issue":"8","key":"517_CR62","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1089\/cap.2015.0127","volume":"26","author":"S Kim","year":"2016","unstructured":"Kim S, Boylan K. Effectiveness of antidepressant medications for symptoms of irritability and disruptive behaviors in children and adolescents. J Child Adolesc Psychopharmacol. 2016;26(8):694\u2013704. https:\/\/doi.org\/10.1089\/cap.2015.0127.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"517_CR63","doi-asserted-by":"publisher","unstructured":"Barnhill LJ. Basic psychopharmacology. In: Rubin I, Merrick J, Greydanus DE, et al. The health care for people with intellectual and developmental disabilities across the lifespan. 3rd ed. Switzerland, Springer International Publishing; 2016: p. 1585\u2013600. https:\/\/doi.org\/10.1007\/978-3-319-18096-0.","DOI":"10.1007\/978-3-319-18096-0"},{"issue":"6","key":"517_CR64","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1352\/0895-8017(2002)107<0433:BPAPSI>2.0.CO;2","volume":"107","author":"BL Baker","year":"2002","unstructured":"Baker BL, Blacher J, Crnic KA, et al. Behavior problems and parenting stress in families of three-year-old children with and without developmental delays. Am J Ment Retard AJMR. 2002;107(6):433\u201344. https:\/\/doi.org\/10.1352\/0895-8017(2002)107%3c0433:BPAPSI%3e2.0.CO;2.","journal-title":"Am J Ment Retard AJMR."},{"issue":"6","key":"517_CR65","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00213-013-3068-y","volume":"231","author":"LC Politte","year":"2014","unstructured":"Politte LC, McDougle CJ. Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharmacology. 2014;231(6):1023\u201336. https:\/\/doi.org\/10.1007\/s00213-013-3068-y.","journal-title":"Psychopharmacology"},{"issue":"4","key":"517_CR66","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s10567-008-0037-9","volume":"11","author":"N Heilbron","year":"2008","unstructured":"Heilbron N, Prinstein MJ. A review and reconceptualization of social aggression: adaptive and maladaptive correlates. Clin Child Fam Psychol Rev. 2008;11(4):176\u2013217. https:\/\/doi.org\/10.1007\/s10567-008-0037-9.","journal-title":"Clin Child Fam Psychol Rev"},{"issue":"1","key":"517_CR67","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1176\/ajp.143.1.35","volume":"143","author":"SC Yudofsky","year":"1986","unstructured":"Yudofsky SC, Silver JM, Jackson W, et al. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry. 1986;143(1):35\u20139. https:\/\/doi.org\/10.1176\/ajp.143.1.35.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"517_CR68","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/00004583-199703000-00008","volume":"36","author":"B Vitiello","year":"1997","unstructured":"Vitiello B, Stoff DM. Subtypes of aggression and their relevance to child psychiatry. J Am Acad Child Adolesc Psychiatry. 1997;36(3):307\u201315. https:\/\/doi.org\/10.1097\/00004583-199703000-00008.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"517_CR69","doi-asserted-by":"publisher","unstructured":"Pedersen WC, Ellison J, Miller N. Displaced aggression is alive and well. In: Sturmey. The Wiley handbook of violence and aggression. Oxford, UK, Wiley, Oxford; 2017: p. 1\u201313. https:\/\/doi.org\/10.1002\/9781119057574.whbva033.","DOI":"10.1002\/9781119057574.whbva033"},{"issue":"6","key":"517_CR70","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1176\/appi.ajp.2012.11081259","volume":"169","author":"EF Coccaro","year":"2012","unstructured":"Coccaro EF. Intermittent explosive disorder as a disorder of impulsive aggression for DSM-5. Am J Psychiatry. 2012;169(6):577\u201388. https:\/\/doi.org\/10.1176\/appi.ajp.2012.11081259.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"517_CR71","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.psc.2012.08.009","volume":"35","author":"WJ Newman","year":"2012","unstructured":"Newman WJ. Psychopharmacologic management of aggression. Psychiatr Clin. 2012;35(4):957\u201372. https:\/\/doi.org\/10.1016\/j.psc.2012.08.009.","journal-title":"Psychiatr Clin"},{"issue":"1","key":"517_CR72","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1192\/apt.bp.108.005587","volume":"17","author":"D Bramble","year":"2011","unstructured":"Bramble D. Psychopharmacology in children with intellectual disability. Adv Psychiatr Treat. 2011;17(1):32\u201340. https:\/\/doi.org\/10.1192\/apt.bp.108.005587.","journal-title":"Adv Psychiatr Treat"},{"issue":"Pt 3","key":"517_CR73","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1348\/135910701169197","volume":"6","author":"L Wiggs","year":"2001","unstructured":"Wiggs L, Stores G. Behavioural treatment for sleep problems in children with severe intellectual disabilities and daytime challenging behaviour: effect on mothers andfFathers. Br J Health Psychol. 2001;6(Pt 3):257\u201369. https:\/\/doi.org\/10.1348\/135910701169197.","journal-title":"Br J Health Psychol"},{"issue":"3","key":"517_CR74","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1046\/j.1365-2788.2001.00314.x","volume":"45","author":"H Firth","year":"2001","unstructured":"Firth H, Balogh R, Berney T, et al. Psychopathology of sexual abuse in young people with intellectual disability. J Intellect Disabil Res. 2001;45(3):244\u201352. https:\/\/doi.org\/10.1046\/j.1365-2788.2001.00314.x.","journal-title":"J Intellect Disabil Res"},{"issue":"2","key":"517_CR75","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1365-2788.2010.01337.x","volume":"55","author":"K Arron","year":"2011","unstructured":"Arron K, Oliver C, Moss J, et al. The prevalence and phenomenology of self-injurious and aggressive behaviour in genetic syndromes. J Intellect Disabil Res. 2011;55(2):109\u201320. https:\/\/doi.org\/10.1111\/j.1365-2788.2010.01337.x.","journal-title":"J Intellect Disabil Res"},{"key":"517_CR76","doi-asserted-by":"crossref","unstructured":"Pringsheim T, Hirsch L, Gardner D, et al. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Can J Psychiatry. 2015;60(2):42\u201351.","DOI":"10.1177\/070674371506000202"},{"issue":"3","key":"517_CR77","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/19315864.2012.661033","volume":"6","author":"L Christensen","year":"2013","unstructured":"Christensen L, Baker BL, Blacher J. Oppositional defiant disorder in children with intellectual disabilities. J Ment Health Res Intellect Disabil. 2013;6(3):225\u201344. https:\/\/doi.org\/10.1080\/19315864.2012.661033.","journal-title":"J Ment Health Res Intellect Disabil."},{"issue":"4","key":"517_CR78","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4088\/jcp.v62n0405","volume":"62","author":"JK Buitelaar","year":"2001","unstructured":"Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001;62(4):239\u201348. https:\/\/doi.org\/10.4088\/jcp.v62n0405.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"517_CR79","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1177\/1744629520905175","volume":"25","author":"EE Reurts","year":"2021","unstructured":"Reurts EE, Troost PW, Dinnissen M, et al. Aripiprazole in youth with intellectual disabilities: a retrospective chart study. J Intellect Disabil. 2021;25(4):449\u201357. https:\/\/doi.org\/10.1177\/1744629520905175.","journal-title":"J Intellect Disabil"},{"issue":"5","key":"517_CR80","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1089\/cap.2006.16.549","volume":"16","author":"MR Valicenti-McDermott","year":"2006","unstructured":"Valicenti-McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol. 2006;16(5):549\u201360. https:\/\/doi.org\/10.1089\/cap.2006.16.549.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"517_CR81","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.rasd.2012.08.001","volume":"7","author":"D Cohen","year":"2013","unstructured":"Cohen D, Raffin M, Canitano R, et al. Risperidone or aripiprazole in children and adolescents with autism and\/or intellectual disability: a Bayesian meta-analysis of efficacy and secondary effects. Res Autism Spectr Disord. 2013;7(1):167\u201375. https:\/\/doi.org\/10.1016\/j.rasd.2012.08.001.","journal-title":"Res Autism Spectr Disord"},{"issue":"5","key":"517_CR82","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.neubiorev.2011.01.002","volume":"35","author":"FJ Symons","year":"2011","unstructured":"Symons FJ. Self-injurious behavior in neurodevelopmental disorders: relevance of nociceptive and immune mechanisms. Neurosci Biobehav Rev. 2011;35(5):1266\u201374. https:\/\/doi.org\/10.1016\/j.neubiorev.2011.01.002.","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"517_CR83","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1352\/0895-8017(2001)106<0189:EDOSIB>2.0.CO;2","volume":"106","author":"S Hall","year":"2001","unstructured":"Hall S, Oliver C, Murphy G. Early development of self-injurious behavior: an empirical study. Am J Ment Retard. 2001;106(2):189\u201399. https:\/\/doi.org\/10.1352\/0895-8017(2001)106%3c0189:EDOSIB%3e2.0.CO;2.","journal-title":"Am J Ment Retard"},{"issue":"2","key":"517_CR84","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ridd.2012.10.004","volume":"34","author":"L Davies","year":"2013","unstructured":"Davies L, Oliver C. The age related prevalence of aggression and self-injury in persons with an intellectual disability: a review. Res Dev Disabil. 2013;34(2):764\u201375. https:\/\/doi.org\/10.1016\/j.ridd.2012.10.004.","journal-title":"Res Dev Disabil"},{"issue":"4","key":"517_CR85","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.paid.2006.07.021","volume":"42","author":"L Claes","year":"2007","unstructured":"Claes L, Vandereycken W, Vertommen H. Self-injury in female versus male psychiatric patients: a comparison of characteristics, psychopathology and aggression regulation. Personal Individ Differ. 2007;42(4):611\u201321. https:\/\/doi.org\/10.1016\/j.paid.2006.07.021.","journal-title":"Personal Individ Differ"},{"issue":"2","key":"517_CR86","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/1098-2779(2000)6:2<125::AID-MRDD6>3.0.CO;2-T","volume":"6","author":"A Dimitropoulos","year":"2000","unstructured":"Dimitropoulos A, Feurer ID, Roof E, et al. Appetitive behavior, compulsivity, and neurochemistry in Prader-Willi syndrome. Ment Retard Dev Disabil Res Rev. 2000;6(2):125\u201330. https:\/\/doi.org\/10.1002\/1098-2779(2000)6:2%3c125::AID-MRDD6%3e3.0.CO;2-T.","journal-title":"Ment Retard Dev Disabil Res Rev"},{"issue":"1","key":"517_CR87","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1750-1172-6-68","volume":"6","author":"HH Jung","year":"2011","unstructured":"Jung HH, Danek A, Walker RH. Neuroacanthocytosis syndromes. Orphanet J Rare Dis. 2011;6(1):68. https:\/\/doi.org\/10.1186\/1750-1172-6-68.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"517_CR88","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1098-2779(200102)7:1<3::AID-MRDD1002>3.0.CO;2-#","volume":"7","author":"SR Schroeder","year":"2001","unstructured":"Schroeder SR, Oster-Granite ML, Berkson G, et al. Self-injurious behavior: gene-brain-behavior relationships. Ment Retard Dev Disabil Res Rev. 2001;7(1):3\u201312. https:\/\/doi.org\/10.1002\/1098-2779(200102)7:1%3c3::AID-MRDD1002%3e3.0.CO;2-#.","journal-title":"Ment Retard Dev Disabil Res Rev"},{"issue":"4","key":"517_CR89","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/0891-4222(93)90026-g","volume":"14","author":"WD Crews","year":"1993","unstructured":"Crews WD, Bonaventura S, Rowe FB, et al. Cessation of long-term naltrexone therapy and self-injury: a case study. Res Dev Disabil. 1993;14(4):331\u201340. https:\/\/doi.org\/10.1016\/0891-4222(93)90026-g.","journal-title":"Res Dev Disabil"},{"issue":"6","key":"517_CR90","first-page":"654","volume":"100","author":"MH Lewis","year":"1996","unstructured":"Lewis MH, Bodfish JW, Powell SB, et al. Clomipramine treatment for self-injurious behavior of individuals with mental retardation: a double-blind comparison with placebo. Am J Ment Retard. 1996;100(6):654\u201365.","journal-title":"Am J Ment Retard"},{"issue":"3","key":"517_CR91","first-page":"372","volume":"25","author":"DJ Luchins","year":"1989","unstructured":"Luchins DJ, Dojka D. Lithium and propranolol in aggression and self-injurious behavior in the mentally retarded. Psychopharmacol Bull. 1989;25(3):372\u20135.","journal-title":"Psychopharmacol Bull"},{"issue":"10","key":"517_CR92","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.4088\/jcp.v64n1018","volume":"64","author":"DS Janowsky","year":"2003","unstructured":"Janowsky DS, Barnhill LJ, Davis JM. Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. J Clin Psychiatry. 2003;64(10):1258\u201365. https:\/\/doi.org\/10.4088\/jcp.v64n1018.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"517_CR93","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1352\/0895-8017(1998)102<0427:ptoaas>2.0.co;2","volume":"102","author":"PA Davanzo","year":"1998","unstructured":"Davanzo PA, Belin TR, Widawski MH, et al. Paroxetine treatment of aggression and self-injury in persons with mental retardation. Am J Ment Retard. 1998;102(5):427\u201337. https:\/\/doi.org\/10.1352\/0895-8017(1998)102%3c0427:ptoaas%3e2.0.co;2.","journal-title":"Am J Ment Retard"},{"issue":"2","key":"517_CR94","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/YCO.0000000000000233","volume":"29","author":"NY Ji","year":"2016","unstructured":"Ji NY, Findling RL. Pharmacotherapy for mental health problems in people with intellectual disability. Curr Opin Psychiatry. 2016;29(2):103\u201325. https:\/\/doi.org\/10.1097\/YCO.0000000000000233.","journal-title":"Curr Opin Psychiatry"},{"issue":"9","key":"517_CR95","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3928\/0090-4481-20070901-09","volume":"36","author":"CA Erickson","year":"2007","unstructured":"Erickson CA, Posey DJ, Stigler KA, et al. Pharmacologic treatment of autism and related disorders. Pediatr Ann. 2007;36(9):575\u201385. https:\/\/doi.org\/10.3928\/0090-4481-20070901-09.","journal-title":"Pediatr Ann"},{"issue":"2","key":"517_CR96","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/0091217417720896","volume":"52","author":"RM Molina-Ruiz","year":"2017","unstructured":"Molina-Ruiz RM, Mart\u00edn-Carballeda J, Asensio-Moreno I, et al. A guide to psychopharmacological treatment of patients with intellectual disability in psychiatry. Int J Psychiatry Med. 2017;52(2):176\u201389. https:\/\/doi.org\/10.1177\/0091217417720896.","journal-title":"Int J Psychiatry Med"},{"issue":"4","key":"517_CR97","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2217\/phe.10.45","volume":"4","author":"K Blankenship","year":"2010","unstructured":"Blankenship K, Erickson CA, Stigler KA, et al. Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6\u201317 years. Pediatr Health. 2010;4(4):375\u201381. https:\/\/doi.org\/10.2217\/phe.10.45.","journal-title":"Pediatr Health"},{"issue":"11","key":"517_CR98","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","volume":"48","author":"RN Marcus","year":"2009","unstructured":"Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110\u20139. https:\/\/doi.org\/10.1097\/CHI.0b013e3181b76658.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"517_CR99","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.ridd.2014.03.006","volume":"35","author":"MG Aman","year":"2014","unstructured":"Aman MG, Smith T, Arnold LE, et al. A review of atomoxetine effects in young people with developmental disabilities. Res Dev Disabil. 2014;35(6):1412\u201324. https:\/\/doi.org\/10.1016\/j.ridd.2014.03.006.","journal-title":"Res Dev Disabil"},{"key":"517_CR100","doi-asserted-by":"crossref","unstructured":"Hurwitz R, Blackmore R, Hazell P, et al. Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents. Cochrane Database Syst Rev. 2012;(3):CD008372.","DOI":"10.1002\/14651858.CD008372.pub2"},{"issue":"3","key":"517_CR101","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1089\/10445460152595586","volume":"11","author":"DJ Posey","year":"2001","unstructured":"Posey DJ, Guenin KD, Kohn AE, et al. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2001;11(3):267\u201377. https:\/\/doi.org\/10.1089\/10445460152595586.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"517_CR102","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1352\/0895-8017(2002)107<0376:BBSERA>2.0.CO;2","volume":"107","author":"JE Kalachnik","year":"2002","unstructured":"Kalachnik JE, Hanzel TE, Sevenich R, et al. Benzodiazepine behavioral side effects: review and implications for individuals with mental retardation. Am J Ment Retard AJMR. 2002;107(5):376\u2013410.","journal-title":"Am J Ment Retard AJMR."},{"issue":"12","key":"517_CR103","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1192\/pb.26.12.460","volume":"26","author":"C Paton","year":"2002","unstructured":"Paton C. Benzodiazepines and disinhibition: a review. Psychiatr Bull. 2002;26(12):460\u20132. https:\/\/doi.org\/10.1192\/pb.26.12.460.","journal-title":"Psychiatr Bull"},{"issue":"5","key":"517_CR104","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/jcpp.12812","volume":"59","author":"O Bruni","year":"2018","unstructured":"Bruni O, Angriman M, Calisti F, et al. Practitioner review: treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities. J Child Psychol Psychiatry. 2018;59(5):489\u2013508. https:\/\/doi.org\/10.1111\/jcpp.12812.","journal-title":"J Child Psychol Psychiatry"},{"issue":"1","key":"517_CR105","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1089\/cap.2017.0060","volume":"28","author":"JR Strawn","year":"2018","unstructured":"Strawn JR, Mills JA, Cornwall GJ, et al. Buspirone in children and adolescents with anxiety: a review and Bayesian analysis of abandoned randomized controlled trials. J Child Adolesc Psychopharmacol. 2018;28(1):2\u20139. https:\/\/doi.org\/10.1089\/cap.2017.0060.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"517_CR106","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1089\/cap.2018.0021","volume":"29","author":"TA Ceranoglu","year":"2019","unstructured":"Ceranoglu TA, Wozniak J, Fried R, et al. A retrospective chart review of buspirone for the treatment of anxiety in psychiatrically referred youth with high-functioning autism spectrum disorder. J Child Adolesc Psychopharmacol. 2019;29(1):28\u201333. https:\/\/doi.org\/10.1089\/cap.2018.0021.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"517_CR107","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jpeds.2015.11.033","volume":"170","author":"DC Chugani","year":"2016","unstructured":"Chugani DC, Chugani HT, Wiznitzer M, et al. Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: a randomized trial. J Pediatr. 2016;170:45-53.e4. https:\/\/doi.org\/10.1016\/j.jpeds.2015.11.033.","journal-title":"J Pediatr"},{"issue":"2","key":"517_CR108","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1007\/s10803-019-04301-9","volume":"50","author":"RP Thom","year":"2020","unstructured":"Thom RP, Keary CJ, Waxler JL, et al. Buspirone for the treatment of generalized anxiety disorder in Williams syndrome: a case series. J Autism Dev Disord. 2020;50(2):676\u201382. https:\/\/doi.org\/10.1007\/s10803-019-04301-9.","journal-title":"J Autism Dev Disord"},{"issue":"2","key":"517_CR109","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/YPG.0000000000000218","volume":"29","author":"K Balaj","year":"2019","unstructured":"Balaj K, Nowinski L, Walsh B, et al. Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome: a case series. Psychiatr Genet. 2019;29(2):51\u20136. https:\/\/doi.org\/10.1097\/YPG.0000000000000218.","journal-title":"Psychiatr Genet"},{"issue":"12","key":"517_CR110","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1016\/j.ridd.2013.08.015","volume":"34","author":"F Ward","year":"2013","unstructured":"Ward F, Tharian P, Roy M, et al. Efficacy of beta blockers in the management of problem behaviours in people with intellectual disabilities: a systematic review. Res Dev Disabil. 2013;34(12):4293\u2013303. https:\/\/doi.org\/10.1016\/j.ridd.2013.08.015.","journal-title":"Res Dev Disabil"},{"key":"517_CR111","doi-asserted-by":"publisher","unstructured":"Department of Psychiatry, GGMC and Sir JJ Group of Hospitals, Ramakrishnan A. A comparative study on efficacy of risperidone versus risperidone and sodium valproate combination in the treatment of aggression in children and adolescents with intellectual disability. J Med Sci Clin Res. 2018;6(5). https:\/\/doi.org\/10.18535\/jmscr\/v6i5.137.","DOI":"10.18535\/jmscr\/v6i5.137"},{"issue":"4","key":"517_CR112","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1089\/cap.2005.15.682","volume":"15","author":"JA Hellings","year":"2005","unstructured":"Hellings JA, Weckbaugh M, Nickel EJ, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005;15(4):682\u201392. https:\/\/doi.org\/10.1089\/cap.2005.15.682.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"517_CR113","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1089\/cap.2006.16.541","volume":"16","author":"E Hollander","year":"2006","unstructured":"Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood\/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006;16(5):541\u20138. https:\/\/doi.org\/10.1089\/cap.2006.16.541.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"517_CR114","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/npp.2009.202","volume":"35","author":"E Hollander","year":"2010","unstructured":"Hollander E, Chaplin W, Soorya L, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2010;35(4):990\u20138. https:\/\/doi.org\/10.1038\/npp.2009.202.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"517_CR115","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1023\/A:1010799115457","volume":"31","author":"KM Belsito","year":"2001","unstructured":"Belsito KM, Law PA, Kirk KS, et al. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2001;31(2):175\u201381. https:\/\/doi.org\/10.1023\/A:1010799115457.","journal-title":"J Autism Dev Disord"},{"issue":"5","key":"517_CR116","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1176\/ajp.2007.164.5.832","volume":"164","author":"S Kapetanovic","year":"2007","unstructured":"Kapetanovic S. Oxcarbazepine in youths with autistic disorder and significant disruptive behaviors. Am J Psychiatry. 2007;164(5):832\u20133. https:\/\/doi.org\/10.1176\/ajp.2007.164.5.832.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"517_CR117","first-page":"73","volume":"3","author":"WC Shin","year":"2006","unstructured":"Shin WC, Song DH, Ha EH, et al. Six-week open-label trial of topiramate to treat disruptive behaviors in children and adolescents with or without mental retardation. Psychiatry Invest. 2006;3(2):73\u201380.","journal-title":"Psychiatry Invest"},{"issue":"3","key":"517_CR118","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1089\/cap.2004.14.426","volume":"14","author":"AY Hardan","year":"2004","unstructured":"Hardan AY, Jou RJ, Handen BL. A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14(3):426\u201332. https:\/\/doi.org\/10.1089\/cap.2004.14.426.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"517_CR119","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00004703-200208000-00006","volume":"23","author":"TA Rugino","year":"2002","unstructured":"Rugino TA, Samsock TC. Levetiracetam in autistic children: an open-label study. J Dev Behav Pediatr. 2002;23(4):225\u201330. https:\/\/doi.org\/10.1097\/00004703-200208000-00006.","journal-title":"J Dev Behav Pediatr"},{"issue":"3","key":"517_CR120","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1089\/10445460152595595","volume":"11","author":"B Spivak","year":"2001","unstructured":"Spivak B, Mozes T, Mester R, et al. Zuclopenthixol treatment of behavioral disturbances in mentally retarded children and adolescents: an open-label study. J Child Adolesc Psychopharmacol. 2001;11(3):279\u201384. https:\/\/doi.org\/10.1089\/10445460152595595.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"517_CR121","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00787-007-0656-6","volume":"17","author":"O Gencer","year":"2008","unstructured":"Gencer O, Emiroglu FNI, Miral S, et al. Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder: an open label maintenance study. Eur Child Adolesc Psychiatry. 2008;17(4):217\u201325. https:\/\/doi.org\/10.1007\/s00787-007-0656-6.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"1","key":"517_CR122","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/01.chi.0000145805.24274.09","volume":"44","author":"J Croonenberghs","year":"2005","unstructured":"Croonenberghs J, Fegert JM, Findling RL, et al. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry. 2005;44(1):64\u201372. https:\/\/doi.org\/10.1097\/01.chi.0000145805.24274.09.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"517_CR123","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2147\/NDT.S151802","volume":"14","author":"N Maneeton","year":"2018","unstructured":"Maneeton N, Maneeton B, Puthisri S, et al. Risperidone for children and adolescents with autism spectrum disorder: a systematic review. Neuropsychiatr Dis Treat. 2018;14:1811\u201320. https:\/\/doi.org\/10.2147\/NDT.S151802.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"01","key":"517_CR124","doi-asserted-by":"publisher","first-page":"035","DOI":"10.1055\/s-0035-1557235","volume":"03","author":"R Jou","year":"2015","unstructured":"Jou R, Handen B, Hardan A. Quetiapine in children and adolescents with subaverage IQ. J Pediatr Neurol. 2015;03(01):035\u20139. https:\/\/doi.org\/10.1055\/s-0035-1557235.","journal-title":"J Pediatr Neurol"},{"issue":"7","key":"517_CR125","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/01.chi.0000219832.23849.31","volume":"45","author":"RL Findling","year":"2006","unstructured":"Findling RL, Reed MD, O\u2019Riordan MA, et al. Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(7):792\u2013800. https:\/\/doi.org\/10.1097\/01.chi.0000219832.23849.31.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"517_CR126","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1089\/1044546041649129","volume":"14","author":"RL Findling","year":"2004","unstructured":"Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol. 2004;14(2):287\u201394. https:\/\/doi.org\/10.1089\/1044546041649129.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"517_CR127","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10803-005-3306-1","volume":"35","author":"AY Hardan","year":"2005","unstructured":"Hardan AY, Jou RJ, Handen BL. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord. 2005;35(3):387\u201391. https:\/\/doi.org\/10.1007\/s10803-005-3306-1.","journal-title":"J Autism Dev Disord"},{"issue":"8","key":"517_CR128","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1097\/01.chi.0000223312.48406.6e","volume":"45","author":"BL Handen","year":"2006","unstructured":"Handen BL, Hardan AY. Open-label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavioral disorders. J Am Acad Child Adolesc Psychiatry. 2006;45(8):928\u201335. https:\/\/doi.org\/10.1097\/01.chi.0000223312.48406.6e.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"517_CR129","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1097\/00004583-200208000-00010","volume":"41","author":"CJ Mcdougle","year":"2002","unstructured":"Mcdougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry. 2002;41(8):921\u20137. https:\/\/doi.org\/10.1097\/00004583-200208000-00010.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"517_CR130","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00213-012-2711-3","volume":"223","author":"KA Stigler","year":"2012","unstructured":"Stigler KA, Mullett JE, Erickson CA, et al. Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology. 2012;223(2):237\u201345. https:\/\/doi.org\/10.1007\/s00213-012-2711-3.","journal-title":"Psychopharmacology"},{"issue":"3","key":"517_CR131","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/JCP.0b013e318218f4a1","volume":"31","author":"L Beherec","year":"2011","unstructured":"Beherec L, Lambrey S, Quilici G, et al. Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors. J Clin Psychopharmacol. 2011;31(3):341\u20134. https:\/\/doi.org\/10.1097\/JCP.0b013e318218f4a1.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"517_CR132","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s10803-015-2628-x","volume":"46","author":"A Loebel","year":"2016","unstructured":"Loebel A, Brams M, Goldman RS, et al. Lurasidone for the treatment of irritability associated with autistic disorder. J Autism Dev Disord. 2016;46(4):1153\u201363. https:\/\/doi.org\/10.1007\/s10803-015-2628-x.","journal-title":"J Autism Dev Disord"},{"issue":"10","key":"517_CR133","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1089\/cap.2016.0042","volume":"26","author":"IR McGrane","year":"2016","unstructured":"McGrane IR, Loveland JG, Zaluski HJ. Adjunctive amantadine treatment for aggressive behavior in children: a series of eight cases. J Child Adolesc Psychopharmacol. 2016;26(10):935\u20138. https:\/\/doi.org\/10.1089\/cap.2016.0042.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"517_CR134","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/00004583-200106000-00010","volume":"40","author":"BH King","year":"2001","unstructured":"King BH, Wright DM, Handen BL, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40(6):658\u201365. https:\/\/doi.org\/10.1097\/00004583-200106000-00010.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"517_CR135","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1176\/appi.ajp.2015.15010055","volume":"172","author":"L Scahill","year":"2015","unstructured":"Scahill L, McCracken JT, King BH, et al. Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. Am J Psychiatry. 2015;172(12):1197\u2013206. https:\/\/doi.org\/10.1176\/appi.ajp.2015.15010055.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"517_CR136","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1352\/0047-6765(2001)039<0259:DBPCTO>2.0.CO;2","volume":"39","author":"V Agarwal","year":"2001","unstructured":"Agarwal V, Sitholey P, Kumar S, et al. Double-blind, placebo-controlled trial of clonidine in hyperactive children with mental retardation. Ment Retard. 2001;39(4):259\u201367. https:\/\/doi.org\/10.1352\/0047-6765(2001)039%3c0259:DBPCTO%3e2.0.CO;2.","journal-title":"Ment Retard"},{"key":"517_CR137","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.1888","author":"S Naveed","year":"2017","unstructured":"Naveed S, Amray A, Waqas A, et al. Use of N-acetylcysteine in psychiatric conditions among children and adolescents: a scoping review. Cureus. 2017. https:\/\/doi.org\/10.7759\/cureus.1888.","journal-title":"Cureus."},{"issue":"7","key":"517_CR138","doi-asserted-by":"publisher","first-page":"675","DOI":"10.5863\/1551-6776-26.7.675","volume":"26","author":"SL Stancil","year":"2021","unstructured":"Stancil SL, Abdel-Rahman S, Wagner J. Developmental considerations for the use of naltrexone in children and adolescents. J Pediatr Pharmacol Ther. 2021;26(7):675\u201395. https:\/\/doi.org\/10.5863\/1551-6776-26.7.675.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"2","key":"517_CR139","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/bcp.14399","volume":"87","author":"D Efron","year":"2021","unstructured":"Efron D, Freeman JL, Cranswick N, et al. A pilot randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability. Br J Clin Pharmacol. 2021;87(2):436\u201346. https:\/\/doi.org\/10.1111\/bcp.14399.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"517_CR140","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s10803-018-3808-2","volume":"49","author":"A Aran","year":"2019","unstructured":"Aran A, Cassuto H, Lubotzky A, et al. Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems: a retrospective feasibility study. J Autism Dev Disord. 2019;49(3):1284\u20138. https:\/\/doi.org\/10.1007\/s10803-018-3808-2.","journal-title":"J Autism Dev Disord"},{"issue":"1","key":"517_CR141","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13229-021-00420-2","volume":"12","author":"A Aran","year":"2021","unstructured":"Aran A, Harel M, Cassuto H, et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Mol Autism. 2021;12(1):6. https:\/\/doi.org\/10.1186\/s13229-021-00420-2.","journal-title":"Mol Autism."},{"issue":"1","key":"517_CR142","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41598-018-37570-y","volume":"9","author":"L Bar-Lev Schleider","year":"2019","unstructured":"Bar-Lev Schleider L, Mechoulam R, Saban N, et al. Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep. 2019;9(1):200. https:\/\/doi.org\/10.1038\/s41598-018-37570-y.","journal-title":"Sci Rep"},{"key":"517_CR143","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3389\/fphar.2018.01521","volume":"9","author":"D Barchel","year":"2019","unstructured":"Barchel D, Stolar O, De-Haan T, et al. Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Front Pharmacol. 2019;9:1521. https:\/\/doi.org\/10.3389\/fphar.2018.01521.","journal-title":"Front Pharmacol"},{"issue":"3","key":"517_CR144","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1192\/apt.bp.113.011577","volume":"20","author":"A Ali","year":"2014","unstructured":"Ali A, Blickwedel J, Hassiotis A. Interventions for challenging behaviour in intellectual disability. Adv Psychiatr Treat. 2014;20(3):184\u201392. https:\/\/doi.org\/10.1192\/apt.bp.113.011577.","journal-title":"Adv Psychiatr Treat"},{"issue":"S1","key":"517_CR145","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00702-014-1219-x","volume":"122","author":"F H\u00e4\u03b2ler","year":"2015","unstructured":"H\u00e4\u03b2ler F, Thome J, Reis O. Polypharmacy in the treatment of subjects with intellectual disability. J Neural Transm. 2015;122(S1):93\u2013100. https:\/\/doi.org\/10.1007\/s00702-014-1219-x.","journal-title":"J Neural Transm"},{"issue":"6","key":"517_CR146","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s10882-017-9570-0","volume":"29","author":"MG Valdovinos","year":"2017","unstructured":"Valdovinos MG, Schieber E, McMahon M, et al. Adverse side effects of psychotropic medication and challenging behavior: pilot work assessing impact. J Dev Phys Disabil. 2017;29(6):969\u201382. https:\/\/doi.org\/10.1007\/s10882-017-9570-0.","journal-title":"J Dev Phys Disabil"},{"issue":"1","key":"517_CR147","first-page":"110","volume":"95","author":"SL Ruedrich","year":"1990","unstructured":"Ruedrich SL, Grush L, Wilson J. Beta adrenergic blocking medications for aggressive or self-injurious mentally retarded persons. Am J Ment Retard. 1990;95(1):110\u20139.","journal-title":"Am J Ment Retard"},{"issue":"3","key":"517_CR148","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1023\/a:1025854532079","volume":"27","author":"JP Horrigan","year":"1997","unstructured":"Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Dev Disord. 1997;27(3):313\u201323. https:\/\/doi.org\/10.1023\/a:1025854532079.","journal-title":"J Autism Dev Disord"},{"issue":"4","key":"517_CR149","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jaac.2019.11.018","volume":"59","author":"M Siegel","year":"2020","unstructured":"Siegel M, McGuire K, Veenstra-VanderWeele J, et al. Practice parameter for the assessment and treatment of psychiatric disorders in children and adolescents with intellectual disability (intellectual developmental disorder). J Am Acad Child Adolesc Psychiatry. 2020;59(4):468\u201396. https:\/\/doi.org\/10.1016\/j.jaac.2019.11.018.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"517_CR150","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","volume":"162","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2005","unstructured":"Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry. 2005;162(7):1361\u20139. https:\/\/doi.org\/10.1176\/appi.ajp.162.7.1361.","journal-title":"Am J Psychiatry"},{"issue":"929","key":"517_CR151","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/pmj.79.929.139","volume":"79","author":"R Antochi","year":"2003","unstructured":"Antochi R, Stavrakaki C, Emery PC. Psychopharmacological treatments in persons with dual diagnosis of psychiatric disorders and developmental disabilities. Postgrad Med J. 2003;79(929):139\u201346. https:\/\/doi.org\/10.1136\/pmj.79.929.139.","journal-title":"Postgrad Med J"},{"issue":"4","key":"517_CR152","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/00004583-199207000-00024","volume":"31","author":"EH Cook","year":"1992","unstructured":"Cook EH, Rowlett R, Jaselskis C, et al. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry. 1992;31(4):739\u201345. https:\/\/doi.org\/10.1097\/00004583-199207000-00024.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"517_CR153","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/00004583-199103000-00012","volume":"30","author":"BL Handen","year":"1991","unstructured":"Handen BL, Feldman H, Gosling A, et al. Adverse side effects of methylphenidate among mentally retarded children with ADHD. J Am Acad Child Adolesc Psychiatry. 1991;30(2):241\u20135. https:\/\/doi.org\/10.1097\/00004583-199103000-00012.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"517_CR154","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jaac.2011.10.012","volume":"51","author":"TE Wilens","year":"2012","unstructured":"Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):74-85.e2. https:\/\/doi.org\/10.1016\/j.jaac.2011.10.012.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"517_CR155","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2165\/11537790-000000000-00000","volume":"24","author":"DF Connor","year":"2010","unstructured":"Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6\u201312 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010;24(9):755\u201368. https:\/\/doi.org\/10.2165\/11537790-000000000-00000.","journal-title":"CNS Drugs"},{"issue":"6","key":"517_CR156","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jaac.2018.09.434","volume":"58","author":"MHF Deutz","year":"2019","unstructured":"Deutz MHF, Woltering S, Vossen HGM, et al. Underlying psychophysiology of dysregulation: resting heart rate and heart rate reactivity in relation to childhood dysregulation. J Am Acad Child Adolesc Psychiatry. 2019;58(6):589\u201399. https:\/\/doi.org\/10.1016\/j.jaac.2018.09.434.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"517_CR157","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/jar.12720","volume":"33","author":"F Scheffers","year":"2020","unstructured":"Scheffers F, Vugt E, Moonen X. Resilience in the face of adversity in adults with an intellectual disability: a literature review. J Appl Res Intellect Disabil. 2020;33(5):828\u201338. https:\/\/doi.org\/10.1111\/jar.12720.","journal-title":"J Appl Res Intellect Disabil"},{"issue":"3","key":"517_CR158","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.3.e34","volume":"110","author":"A Turgay","year":"2002","unstructured":"Turgay A, Binder C, Snyder R, et al. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics. 2002;110(3): e34. https:\/\/doi.org\/10.1542\/peds.110.3.e34.","journal-title":"Pediatrics"},{"issue":"1","key":"517_CR159","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1080\/09540261.2018.1458706","volume":"30","author":"R Goel","year":"2018","unstructured":"Goel R, Hong JS, Findling RL, et al. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. Int Rev Psychiatry. 2018;30(1):78\u201395. https:\/\/doi.org\/10.1080\/09540261.2018.1458706.","journal-title":"Int Rev Psychiatry"},{"issue":"4","key":"517_CR160","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/WCO.0000000000000703","volume":"32","author":"H Yamasue","year":"2019","unstructured":"Yamasue H, Aran A, Berry-Kravis E. Emerging pharmacological therapies in Fragile X syndrome and autism. Curr Opin Neurol. 2019;32(4):635\u201340. https:\/\/doi.org\/10.1097\/WCO.0000000000000703.","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"517_CR161","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/diseases7010024","volume":"7","author":"H Higashida","year":"2019","unstructured":"Higashida H, Munesue T, Kosaka H, et al. Social interaction improved by oxytocin in the subclass of autism with comorbid intellectual disabilities. Diseases. 2019;7(1):24. https:\/\/doi.org\/10.3390\/diseases7010024.","journal-title":"Diseases"},{"issue":"1","key":"517_CR162","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12888-020-2477-9","volume":"20","author":"Y Yu","year":"2020","unstructured":"Yu Y, Chaulagain A, Pedersen SA, et al. Pharmacotherapy of restricted\/repetitive behavior in autism spectrum disorder: a systematic review and meta-analysis. BMC Psychiatry. 2020;20(1):121. https:\/\/doi.org\/10.1186\/s12888-020-2477-9.","journal-title":"BMC Psychiatry"},{"issue":"6","key":"517_CR163","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00787-020-01587-4","volume":"30","author":"J Fuentes","year":"2021","unstructured":"Fuentes J, Herv\u00e1s A, Howlin P, et al. ESCAP practice guidance for autism: a summary of evidence-based recommendations for diagnosis and treatment. Eur Child Adolesc Psychiatry. 2021;30(6):961\u201384. https:\/\/doi.org\/10.1007\/s00787-020-01587-4.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"517_CR164","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neubiorev.2020.12.028","volume":"122","author":"Y Huang","year":"2021","unstructured":"Huang Y, Huang X, Ebstein RP, et al. Intranasal oxytocin in the treatment of autism spectrum disorders: a multilevel meta-analysis. Neurosci Biobehav Rev. 2021;122:18\u201327. https:\/\/doi.org\/10.1016\/j.neubiorev.2020.12.028.","journal-title":"Neurosci Biobehav Rev"},{"issue":"6","key":"517_CR165","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.ridd.2010.07.017","volume":"31","author":"P Poppes","year":"2010","unstructured":"Poppes P, van der Putten AJJ, Vlaskamp C. Frequency and severity of challenging behaviour in people with profound intellectual and multiple disabilities. Res Dev Disabil. 2010;31(6):1269\u201375. https:\/\/doi.org\/10.1016\/j.ridd.2010.07.017.","journal-title":"Res Dev Disabil"},{"key":"517_CR166","unstructured":"NIMH. Research domain criteria (RDoC). Available from: https:\/\/www.nimh.nih.gov\/research\/research-funded-by-nimh\/rdoc. Accessed 29 Oct 2021."},{"issue":"5","key":"517_CR167","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1176\/ajp.153.5.738a","volume":"153","author":"A Zuddas","year":"1996","unstructured":"Zuddas A, Ledda MG, Fratta A, et al. Clinical effects of clozapine on autistic disorder. Am J Psychiatry. 1996;153(5):738. https:\/\/doi.org\/10.1176\/ajp.153.5.738a.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"517_CR168","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/cap.2009.0057","volume":"20","author":"S Lambrey","year":"2010","unstructured":"Lambrey S, Falissard B, Martin-Barrero M, et al. Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder. J Child Adolesc Psychopharmacol. 2010;20(1):79\u201380. https:\/\/doi.org\/10.1089\/cap.2009.0057.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"517_CR169","doi-asserted-by":"publisher","first-page":"479","DOI":"10.4088\/jcp.v62n0612h","volume":"62","author":"NC Chen","year":"2001","unstructured":"Chen NC, Bedair HS, McKay B, et al. Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry. 2001;62(6):479\u201380. https:\/\/doi.org\/10.4088\/jcp.v62n0612h.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"517_CR170","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1089\/cap.1999.9.99","volume":"9","author":"A Martin","year":"1999","unstructured":"Martin A, Koenig K, Scahill L, et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 1999;9(2):99\u2013107. https:\/\/doi.org\/10.1089\/cap.1999.9.99.","journal-title":"J Child Adolesc Psychopharmacol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00517-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-022-00517-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00517-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T04:15:23Z","timestamp":1662092123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-022-00517-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":170,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["517"],"URL":"https:\/\/doi.org\/10.1007\/s40272-022-00517-y","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,4]]},"assertion":[{"value":"24 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There were no sources of financial assistance used or received in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}